BUZZ-Janux plunges after early-stage data for prostate cancer drug
Reuters
Yesterday
BUZZ-Janux plunges after early-stage data for prostate cancer drug
** Shares of drug developer Janux TherapeuticsJANX.O fall 44% to $18.99 premarket
** Co says early-stage trial of JANX007 in advanced prostate cancer met main goals with durable responses and manageable safety
** Shares drop as results aligned with analyst expectations but fell short of lofty buyside hopes, says brokerage BTIG
** JANX says men with advanced prostate cancer saw disease remain stable for about 8–9 months on JANX007
** In chemo-naive patients, drug led to rapid and significant declines in prostate-specific antigen, a key cancer marker
** Up to last close, stock down ~37% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.